Niche or independent: who controls what?

In June 2023, announcing the largest acquisition in its short history, the trade press described Creed as “the largest global independent player in the high-end fragrance market” (Premium Beauty News). At that moment the house was controlled by BlackRock Long Term Private Capital Europe funds. It was sold to Kering, and by 2026 it sat inside L’Oréal, part of the EUR 4bn Kering Beauté disposal (Personal Care Insights).

Three owners in under three years, not one of them independent, and the word survived every transfer. That is the clue. In trade usage “independent” means “not yet owned by an operating conglomerate”, which is a statement about the cap table and about nothing else.

What a bespoke fragrance actually costs to commission

From the other side of the transaction, the price of not being independent is not abstract, it is a line on an invoice.

A bespoke fragrance curation, applied samples included, was invoiced by a British creator at £1,500, about $2,037. We charge at roughly the same level for the same work, so this is a rate we practise and not a market survey. What it buys is the creation of the juice, and that is all: stability testing, container compatibility and the regulatory file are separate work, quoted separately.

Set that beside a full cosmetic development. A French contract manufacturer’s quote for a three-reference range, from development to notification, came to €10,780 excluding tax: €6,400 of development, €2,240 of laboratory testing, €2,140 of regulatory compliance.

Two things follow that bear directly on ownership. The sums are small enough that a brand can be commissioned into existence for the price of a used car, which is why there are so many of them. And nothing in either quote transfers a formula: the deliverable is a product you can sell, not a composition you can take elsewhere. Ownership is a separate negotiation that most people never open, because at £1,500 it does not feel like the kind of purchase that needs one.

Private label perfume: what 54 units actually buy you

The other end of the same category is easier to price. A brand can exist at 54 units: that is the stated minimum at ALT Fragrances. Privé Label starts at 1,000 pieces with a stock bottle and 10,000 for a dedicated one, and Private Label Perfumery sets the same 1,000 for perfume. Those are not marginal operators, they are the ordinary infrastructure of the category.

So the entry ticket is a few dozen bottles of a juice someone else composed, in a mould someone else owns, against a formula the brand does not hold. Nothing in that sentence is illegitimate, and plenty of good products are made that way. It simply has no relation to what the word independent is doing on the label.

The industry itself prices the difference. Maison 21G markets formula ownership as an option to be secured rather than a default, warning that launching without it means building “on borrowed ground” (Maison 21G). When a supplier sells you the right to own your own formula, the base case is that you do not.

Why origin claims need a contract, from Senegal to Veracruz

A brand that never contracts with a producer has no origin story of its own. It has its supplier’s, repeated. The distinction becomes concrete the moment someone asks a question the marketing deck did not anticipate: which harvest, which region, what the picker was paid, what happened to the yield last season.

This is where the category splits in a way that “niche” never captures. Mexican houses built on local botany and the gowé supply chain in Senegal are doing something structurally different from a label that buys a finished concentrate, whatever their respective revenues say.

Who pays for the allergen breakdown under the EU’s 82-substance list

Since 31 July 2026 the EU allergen list runs to 82 substances instead of 26, and 28 of them are natural extracts. Compliance is not a labelling exercise, it is a documentation chain that has to reach back to whoever made the material.

The trade press is unusually direct about where this lands. “The entrepreneurs behind the brand are very creative but many lack formulating experience, thus are not well-versed in the complexity”, says John Hunter, founder of Hunter Amenities International; first-time founders “come from other sectors and assume regulatory approval is a final checkpoint rather than a continuous process”, adds Anne-Charlotte Lamboley, regulatory affairs manager at Capsum (BeautyMatter).

The operative question is not whether a brand can pass the audit. It is who holds the file. A brand that cannot produce a constituent-level breakdown per batch without asking its supplier is not selling a compliance risk to its retailer, it is selling its supplier’s willingness to answer.

What the next IFRA amendment does to a rented formula

Every amendment forces the same choice on whoever owns the formula: absorb it by swapping a molecule, or rework the structure. A house formulating with single molecules does the first. A house built on absolutes does the second, which is the asymmetry that hit oakmoss and hits naturals generally.

A brand that rents its formula does neither. It is told. It discovers the reformulation as a fait accompli, usually with a delivery date attached, and it cannot benchmark the change because it cannot read the formula that changed. The same event is a decision on one side of the line and a notification on the other.

That is also why the pickaxe-seller dynamic compounds: every new brand that cannot formulate becomes a client of the few houses that can, and every new rule makes formulating harder to start doing.

Four questions that separate a niche label from an independent house

Price, story and size answer nothing. These four do, and each has an operational consequence rather than a rhetorical one:

1. Who owns the formula? If the composition house owns it, the brand cannot move production, cannot second-source, and cannot modify the juice alone.
2. Who contracts the raw material? If no purchase order ever reaches a distiller, the origin narrative belongs to someone else.
3. Who holds the regulatory dossier? Allergen breakdown per batch and IFRA certificate: whoever holds them controls what the brand can promise a buyer.
4. Who decides the next reformulation? Deciding and being informed are not degrees of the same thing.

A house can answer all four and be tiny. A label can fail all four and sell at 300 euros in a marble boutique. That is the whole point: the two words describe different axes, and only one of them survives contact with a supply chain.